Reactive oxygen species (ROS) are important second messengers generated in response to many types of environmental stress. In this setting, changes in intracellular ROS can activate signal transduction pathways that influence how cells react to their environment. In sepsis, a dynamic proinflammatory cellular response to bacterial toxins (e.g. lipopolysaccharide or LPS) leads to widespread organ damage and death. The present study demonstrates for the first time that the activation of Rac1 (a GTP-binding protein), and the subsequent production of ROS, constitutes a major pathway involved in NFB-mediated tumor necrosis factor-␣ (TNF␣) secretion following LPS challenge in macrophages. Expression of a dominant negative mutant of Rac1 (N17Rac1) reduced Rac1 activation, ROS formation, NFB activation, and TNF␣ secretion following LPS stimulation. In contrast, expression of a dominant active form of Rac1 (V12Rac1) mimicked these effects in the absence of LPS stimulation. IKK␣ and IKK␤ were both required downstream modulators of LPS-activated Rac1, since the expression of either of the IKK dominant mutants (IKK␣KM or IKK␤KA) drastically reduced NFBdependent TNF␣ secretion. Moreover, studies using CD14 blocking antibodies suggest that Rac1 induces TNF␣ secretion through a pathway independent of CD14. However, a maximum therapeutic inhibition of LPS-induced TNF␣ secretion occurred when both CD14 and Rac1 pathways were inhibited. Our results suggest that targeting both Rac1-and CD14-dependent pathways could be a useful therapeutic strategy for attenuating the proinflammatory cytokine response during the course of sepsis.
Reactive oxygen species (ROS) are important second messengers generated in response to many types of environmental stress. In this setting, changes in intracellular ROS can activate signal transduction pathways that influence how cells react to their environment. In sepsis, a dynamic proinflammatory cellular response to bacterial toxins (e.g. lipopolysaccharide or LPS) leads to widespread organ damage and death. The present study demonstrates for the first time that the activation of Rac1 (a GTP-binding protein), and the subsequent production of ROS, constitutes a major pathway involved in NFB-mediated tumor necrosis factor-␣ (TNF␣) secretion following LPS challenge in macrophages. Expression of a dominant negative mutant of Rac1 (N17Rac1) reduced Rac1 activation, ROS formation, NFB activation, and TNF␣ secretion following LPS stimulation. In contrast, expression of a dominant active form of Rac1 (V12Rac1) mimicked these effects in the absence of LPS stimulation. IKK␣ and IKK␤ were both required downstream modulators of LPS-activated Rac1, since the expression of either of the IKK dominant mutants (IKK␣KM or IKK␤KA) drastically reduced NFBdependent TNF␣ secretion. Moreover, studies using CD14 blocking antibodies suggest that Rac1 induces TNF␣ secretion through a pathway independent of CD14. However, a maximum therapeutic inhibition of LPS-induced TNF␣ secretion occurred when both CD14 and Rac1 pathways were inhibited. Our results suggest that targeting both Rac1-and CD14-dependent pathways could be a useful therapeutic strategy for attenuating the proinflammatory cytokine response during the course of sepsis.
Septic shock induced by Gram-negative infections kills 50,000 to 100,000 people each year in the United States (1, 2) . Sepsis is a systemic inflammatory response syndrome to a localized or systemic infection that leads to the overproduction of proinflammatory cytokines, such as TNF␣, 1 and the ultimate failure of multiple organ systems. According to the Centers for Disease Control and Prevention, sepsis is the third leading cause of infectious death in the United States (3) .
Lipopolysaccharide (LPS), an endotoxin found in the outer membrane of Gram-negative bacteria (4), is a major trigger of sepsis. Recognition of LPS is crucial for host antimicrobial defense reactions (5, 6) . LPS stimulates mononuclear cells (monocytes and macrophages) and neutrophils to produce immunoregulatory and proinflammatory cytokines (interleukin-1, interleukin-6, TNF-␣, TGF-␤, and prostaglandins) (7) (8) (9) (10) . The myeloid differentiation antigen CD14, a 55-kDa glycosylphosphatidylinositol-anchored membrane glycoprotein (mCD14), has been shown to play essential roles in the activation of human mononuclear phagocytes by LPS (11) (12) (13) . CD14 is expressed predominantly on the surface of monocytes, macrophages, and neutrophils, (11, 14 -16) and it also exists as a soluble plasma protein lacking the glycosylphosphatidylinositol anchor (sCD14) (5, 17) . Both forms have been shown to play crucial roles in the recognition of LPS and in the initiation of cellular immune responses by LPS (11, 14, 18) . LPS-binding protein (LBP), a 60-kDa serum glycoprotein produced by the liver, has also been shown to enhance LPS-induced cytokine production by monocytic cells (19, 20) . LBP binds to the lipid A region of LPS to form an LBP-LPS complex, which then interacts with CD14 to induce cytokine production (16, 21, 22) . Identification of cell surface receptors (e.g. the Toll-like receptors (TLR)), which interact with the LPS-LBP-CD14 complex, has further elucidated the mechanisms of LPS induced signaling pathways (23) .
Although CD14 and LBP are involved in LPS signaling (CD14-dependent pathways), the existence of additional signaling pathways (CD14-independent pathways) have been reported by other investigators (24 -27) . LPS antagonists, lipid Iva, and Rhodobacter sphaeroides lipid A, but not anti-CD14 blocking antibody, inhibited LPS-induced monocyte activation under serum-free conditions (28) . This suggested that these compounds act at a site distinct from CD14. In addition, neither LBP nor CD14 was found to be necessary for LPS-induced activation of bovine macrophages (29) .
Human polymorphonuclear leukocytes are responsible for killing microorganisms and eliminating cellular debris. These functions are mediated by superoxide (O 2 . ) generated by an NADPH-dependent oxidase, as well as other reactive oxygen species (ROS) such as hydrogen peroxide (H 2 O 2 ), and hydroxyl radicals ( ⅐ OH) (30) . The assembly of NADPH oxidase has been shown to be up-regulated in neutrophils exposed to bacterial LPS (31) . Furthermore, DeLeo et al. (31) have demonstrated that LPS priming increased the level of Rac2, a small GTPbinding protein associated with p47 phox and p67 phox (two subunits needed for NADPH oxidase function, p91 phox ) at the membrane. These studies support a role for LPS priming of the respiratory burst in polymorphonuclear leukocytes. In addition, Rac1 (a homolog of Rac2) has been shown to control mitogenic and oncogenic signals through NADPH oxidase superoxide production (32, 33) . However, little is known about a potential role of Rac1-NADPH oxidase complexes in controlling LPS-mediated intracellular signaling pathways. We hypothesized that Rac1 might be involved in LPS-mediated signaling pathways leading to the activation of macrophages. In the present study, we provide functional and biochemical evidence that Rac1 induction of NFB is partially responsible for LPSinduced TNF␣ production. Activation of this pathway by LPS is dependent on Rac1-mediated ROS formation and the subsequent activation of the IKK complex, but appears to be independent of the CD14 receptor. These studies provide further definition of the ROS-mediated signal transduction pathways that contribute to LPS-induced TNF␣ secretion.
EXPERIMENTAL PROCEDURES
Preparation of Recombinant Adenoviruses-Eight recombinant adenoviral vectors expressing either ␤-galactosidase (Ad.CMVLacZ) (34) , catalase (Ad.Cat) (35), a dominant negative mutant of Rac1 (Ad.N17Rac1) (36), a dominant active mutant of Rac1 (Ad.V12Rac1) (37), a dominant negative mutant form (K44M) of IKK␣ (Ad.IKK␣KM), a dominant negative mutant form (K44A) of IKK␤ (Ad.IKK␤KA), a dominant negative mutant form (S32A/S36A) of IB␣ (Ad.IkBM) (38) , or a luciferase reporter gene driven by NFB transcriptional activation (Ad.NFBLuc), were used for functional studies. Ad.IKK␣KM and Ad.IKK␤KA were constructed from pRc-␤ actin plasmids encoding either the dominant negative mutant of IKK␣ (IKK␣KM) or IKK␤ (IKK␤KA) (39) . Fragments encoding the HA-tagged IKK␣KM or IKK␤KA cDNAs were excised by HindIII-NotI restriction digestion from pRc-␤ actin plasmids and blunt subcloned into the EcoRV site of the pAd.CMV-Link1 adenoviral shuttle plasmid. Recombinant adenoviruses were generated in 293 cells according to a procedure described by Anderson et al. (40) . The expression of HA-IKK␣KM or HA-IKK␤KA from these replication defective adenoviral constructs was confirmed by Western blotting. pNFB-Luc plasmid (CLONTECH Laboratories, Inc., Palo Alto, CA) was used to generate Ad.NFBLuc vector. The fragment containing the luciferase gene driven by four tandem copies of the NFB consensus sequence fused to a TATA-like promoter from the herpes simplex virus-thymidine kinase gene was released by KpnI and XbaI double digestion. The KpnI and XbaI fragment was inserted into a promoterless adenoviral shuttle plasmid (pAd5mcspA) (40) and Ad.NFBLuc virus was generated by homologous recombination. Recombinant adenoviral stocks were generated as previously described (41) and were stored in 10 mM Tris with 20% glycerol at Ϫ80°C. The particle titers of adenoviral stocks were determined by A 260 readings and were typically 10 13 DNA particles/ml. The functional titers of adenoviral stocks were determined by plaque titering on 293 cells and expression assays for encoded proteins. Typically the particle/plaque forming unit ratio was equal to 25.
Rac1 Activation Assay-Rac1 activation assays were performed using a modification of a previously described protocol (42) . pGEX-PBD (PBD encodes the p21-binding domain of Pak1, an effector molecule that specifically binds activated Rac1) was kindly provided by Dr. Richard Cerione (43) . GST-PBD fusion protein was purified from DL21 cells (Amersham Pharmacia Biotech, Piscataway, NJ) transformed with pGEX-PBD. Bacteria were grown at 37°C to log phase and treated with 1 mM isopropyl-1-thio-␤-D-galactopyranoside for 2 h. The cells were centrifuged and the cell pellet was resuspended in lysis buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl 2 , 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, and 10 g/ml aprotinin). Cells were then further lysed by 3 rounds of sonication (each lasting for 30 s). The lysate was subsequently centrifuged at 10,000 ϫ g for 15 min, and the fusion protein was isolated from the supernatant using a Bulk GST Purification Kit (Amersham Pharmacia Biotech, Piscataway, NJ). The purified protein appeared as a single band on SDS-PAGE with Coomassie Blue staining. Protein concentrations were determined using the Bradford assay. For selective precipitation of GTP-bound Rac1, the GST-PBD fusion protein (50 g) was prebound to agarose-conjugated anti-GST antibody (20 g) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA; catalog number sc-138 AC) in 500 l of lysis buffer at 4°C overnight. Subsequently, samples were centrifuged at 2500 ϫ g for 5 min and then washed three times with lysis buffer. These PBD-bound agarose beads were used for precipitation of GTP-bound Rac1 from LPS-treated RAW cells as described below.
Confluent monolayers of RAW cells were treated with 0.2 g/ml LPS (Sigma, catalog number L-2630, source Escherichia coli Sertotype 0111-B4, Ͻ1.3% protein, 3,000,000 endotoxin units/mg) and incubated at 37°C for different periods of time (0, 5, 15, and 30 min). Cells were harvested into lysis buffer (20 mM Hepes, pH 7.4, 0.5% Nonidet P-40, 10 mM MgCl 2 , 10 mM ␤-glycerophosphate, 10% glycerol, 10 g/ml leupeptin, 10 g/ml aprotinin) at the various time points by scraping. Precipitation of GTP-bound Rac1 was performed by the addition of 200 g of RAW cell lysate to GST-PBD bound agarose beads for 2 h at 4°C. Samples were then centrifuged at 2,500 ϫ g for 5 min followed by three washes with lysis buffer. After boiling samples at 100°C for 5 min in SDS-PAGE sample buffer followed by centrifugation, samples were loaded onto a 12% SDS-PAGE for Western blotting against anti-Rac1 antibodies. Nitrocellulose filters were blocked (5% non-fat dry milk in 1 ϫ PBST) at 4°C overnight followed by incubation with 0.2 g/ml rabbit polyclonal anti-Rac-1 antibody (Santa Cruz Biotechnologies) diluted in blocking buffer for 1 h at 25°C. Subsequently, the filter was washed and incubated with peroxidase-conjugated anti-rabbit IgG (Roche Molecular Biochemicals, Indianapolis, IN) at 0.9 g/ml for 1 h at 25°C. The filters were finally washed and developed using a chemiluminescence luminol reagent (Santa Cruz Biotechnologies, Santa Cruz, CA) and exposed to x-ray film. For loading controls, anti-GST antibody (B14) (Santa Cruz Biotechnology, catalog number sc-138) was used to probe the filters.
Tissue Culture and Infection-RAW 264.7 cells were obtained from ATCC and grown on 35-mm Petri dishes in Dulbecco's modified Eagle's medium with 10% FBS and 1% penicillin and streptomycin. Adenoviral infections were performed for 2 h at 37°C, in Dulbecco's modified Eagle's medium without FBS. After infections, an equal volume of Dulbecco's modified Eagle's medium with 20% FBS was added to increase the serum concentration to 10% and the infections were continued for a total of 40 h. Most studies used various multiplicities of infection (m.o.i.) to test recombinant adenoviral vectors. In RAW cells, adenoviral infection at an m.o.i. of 5,000 particles/cell gave greater than Ͼ95% transduction as evidenced by transgene expression. A subset of RAW cells (Ͻ5%) appeared to be refractory to adenoviral infection even at m.o.i. of 10,000 particles/cell.
Luciferase Assay and TNF␣ Measurements-The luciferase assay system with Reporter Lysis Buffer (Promega, Inc., catalog number E4030) was used to measure NFB-mediated transcriptional induction according to the manufacturer's protocol. All measurements of luciferase activity (relative light units) were normalized to the protein concentration. The NFB responsive luciferase reporter, Ad.NFBLuc, was used to co-infect cells at an m.o.i. of 5000 particles/cell in these experiments. For TNF␣ protein measurements, a DuoSet ELISA Development System Kit from R&D Systems (Minneapolis, MN, catalog number DY410) was used according to manufacturers instructions. Antioxidant chemicals pyrrolidinedithiocarbamate (PDTC, Sigma, catalog number P-8765) and N-acetylcysteine (NAC, Sigma, catalog number A-8199) were used to treat RAW cells for 1 h at 37°C prior to LPS treatment at doses ranging from 1 to 100 M (PDTC) and 1 to 25 M (NAC).
Electrophoretic Mobility Shift Assays (EMSA)-Nuclear extracts were prepared according to the procedure published by Andrews and Faller (44) . NFB oligos (Promega, Madison, WI, catalog number E329B) were end-labeled using [␥- 32 P]ATP and T4-kinase according to the manufacturers instructions. The mobility shift assays were performed as previously described (45) .
Electron Spin Resonance Spectroscopy (ESR)-ESR was used to detect the production of hydroxyl radicals using a procedure modified from a previously published protocol (46) . Briefly, ESR assays were conducted at room temperature using a Bruker model EMX ESR spectrometer (Bruker, Karlsvuhe, Germany) equipped with a TM 110 cavity and a flat cell (Electron Spin Resonance Core Facility, University of Iowa, IA). Instrument settings were as follows: receiver gain, 1 ϫ 10 6 ; modulation frequency, 100 kHz; microwave power, 40.1 mW; modulation amplitude, 1.0 G; sweep rate, 1.5 G/s. The WINEPR filter function, moving average (n ϭ 5), was used to filter out noise in all spectra. Prior to LPS treatment, RAW cells were serum starved for 15 h, briefly trypsinized, and then resuspended in PBS with 0.5% FBS. The spin trap, 5,5-dimetyl-1-pyrroline N-oxide (DMPO), was added to cells at a final concentration of 50 mM. Cells then were immediately treated with LPS at a concentration of 5 g/ml and the production of ⅐ OH was recorded for 45 min. Since the signal intensity decreased after 30 min, spectra recorded in the first 20 min were used for analysis. This procedure was also performed on RAW cells preinfected with Ad.N17Rac1, Ad.V12Rac1, or Ad.Cat virus at a m.o.i. of 10,000 particles/cell and incubated at 37°C for 48 h prior to ESR analysis.
Dihydroethidium (DHE) Assays-DHE assays were performed according to a modified protocol from Miller and colleagues (47) . Briefly, RAW cells were grown to 70% confluency on 6-well plates and serum starved overnight. The medium was then changed to PBS containing 10 M DHE for 20 min at 37°C prior to LPS stimulation. Cells were stimulated with LPS (5 g/ml) in PBS containing 10 M DHE and 0.5% FBS for 30 min at 37°C. Cells were then scraped off the plates and kept on ice prior to fluorescence-activated cell sorter analysis. For experiments which included superoxide dismutase pretreatments, cells were incubated in PBS containing 1000 units/ml purified superoxide dismutase enzyme (Sigma, catalog number S2525) and 10 M DHE for 20 min prior to LPS treatment. LPS (5 g/ml) stimulation was carried out in PBS containing 10 M DHE, 1000 units/ml superoxide dismutase, and 0.5% FBS for 30 min at 37°C.
Real Time PCR-Total RNA was isolated using the Absolutely RNA RT-PCR Miniprep Kit according to manufacturers instructions (Stratagene, La Jolla, CA). RNA was quantified using the RiboGreen Kit (Molecular Probes, Eugene, OR). Total RNA was reversed transcribed to cDNA using the RETROscript RT-PCR Kit (Ambion, Austin, TX). PCR amplification was then performed in an iCycler iQ Fluorescence Thermocyler (Bio-Rad) as follows: 3 min at 95°C, followed by 45 cycles of 20 s at 95°C, 20 s at 58°C, 20 s at 72°C, and 10 s at 79°C. Fluorescence data was captured during the dwell at 79°C. Data were collected and recorded by iCycler iQ software (Bio-Rad) and expressed as a function of threshold cycle (C t ), the cycle at which the fluorescence intensity in a given reaction tube rises above background. Specific primer sets for murine TLR and HPRT genes were as follows (5Ј 3 3Ј): TLR2 sense, TGGTTCTTTTCCCAAACTGG and antisense, GCTTTCT-TGGGCTTCCTCTT; TLR4 sense ATTGCTTGGCGAATGTTTCT and antisense, GACCCATGAAATTGGCACTC; TLR6 sense TCTGCAA-CATGAGCCAAGAC and antisense, GTTTTGCAACCGATTGTGTG; HPRT sense, CCTCATGGACTGATTATGGAC and antisense, CAGAT-TCAACTTGCGCTCATC. Primers were selected based on nucleotide sequences downloaded from the National Center for Biotechnology Information data bank and designed with software by Steve Rozen and Helen J. Skaletsky ((1998) Primer3, code available at genome.wi.mit-.edu/genomesoftware/other/primer3.html). PCR conditions and data collection dwell temperature were based on melting curve analysis of each amplimer generated by the primers listed above. Data was captured at 4°C below the lowest melting temperature among all amplimers assayed to ensure that primer-dimers were not contributing to the fluorescence signal generated with SYBR Green I DNA Dye. Relative quantitative gene expression was calculated as follows. For each sample assayed, the C t for reactions amplifying TLR2, TLR4, TLR6, and HPRT were determined. HPRT was used as an internal reference. The C t for each TLR gene was then corrected by subtracting the C t for HPRT (⌬C t ). Untreated controls were chosen as the reference samples, and the ⌬C t for all LPS-treated experimental samples were subtracted from the ⌬C t for the control samples (⌬⌬C t ). Finally, LPS-treated TLR2, TLR4, and TLR6 mRNA abundance relative to control TLR2, TLR4, and TLR6 mRNA abundance was calculated by the formula 2
Ϫ(⌬⌬Ct)
. The validity of this approach was confirmed by using serial 10-fold dilutions of templates containing TLR and HPRT genes. Using this set of template mixtures, the amplification efficiencies for TLR2, TLR4, TLR6, and HPRT amplimers were found to be identical.
RESULTS

LPS Activates the Rac1
Pathway-Previous reports have demonstrated that antioxidants significantly inhibit LPS-mediated activation of NFB and subsequent TNF␣ secretion (48, 49) . We hypothesized that Rac1 might be a central molecular regulator of LPS-induced changes in the cellular redox state promoting the induction of proinflammatory signal transduction pathways. In order to test whether Rac1 activity was elevated following LPS treatment, an assay developed by Glaven and colleagues (42) was utilized. This assay was used to specifically detect the abundance of GTP-bound (activated) Rac1 by immunoprecipitation with a GST-PBD fusion protein in a macrophage cell line (RAW). In support of our initial hypothesis, the abundance of GTP-bound Rac1 increased significantly as early as 5 min after treatment of RAW cells with LPS, but not in mock treated controls (Fig. 1) . These studies indicate that Rac1 is activated early during the cellular response to LPS.
Rac1 Modulates LPS-induced NFB Activity and TNF␣ Secretion-TNF␣ secretion following LPS challenge is well known to correlate with the induction of NFB DNA binding activity (48, 50) , which acts at sites in the TNF␣ promoter to induce expression. Given our results demonstrating the activation of Rac1 by LPS, we next sought to determine whether this pathway induces TNF␣ secretion via the NFB signal transduction pathway. To approach this question, RAW cells were infected with a recombinant adenovirus expressing either the dominant negative mutant form of Rac1 (Ad.N17Rac1), or ␤-galactosidase (Ad.CMVLacZ) as a negative control, 48 h prior to LPS stimulation and assessment of TNF␣ levels in the media. As seen as in Fig. 2A , a maximal 41% reduction in TNF␣ secretion was achieved when RAW cells were infected with Ad.N17Rac1 at an m.o.i. 10,000 DNA particles/cell (the infection efficiency was Ͼ95%). This inhibitory response demonstrated a dose-dependent correlation with the particle dose of Ad.N17Rac1 virus used for infection. In contrast, no reduction in TNF␣ secretion was evident when cells were infected with the negative control virus Ad.CMVLacZ.
These results suggest that activation of Rac1 is required for a fraction, but not all, of the LPS-induced TNF␣ secretion. We next sought to investigate whether Rac1-dependent TNF␣ pro- duction following LPS stimulation correlated with the activation of NFB transcriptional activity. To initially test this hypothesis, RAW cells were co-infected with an adenovirus carrying an NFB responsive luciferase reporter gene (Ad.NFBLuc) in combination with Ad.N17Rac1 or Ad.CMVLacZ. Luciferase assays were then performed to assess NFB transcriptional activity. As seen in Fig. 2B , reductions in NFB reporter activity in the presence of N17Rac1 expression closely mirrored reductions seen in TNF␣ production ( Fig. 2A) . Maximal inhibition of NFB transcriptional activity reached 47% when RAW cells were infected with the Ad.N17Rac1 virus at an m.o.i of 10,000 DNA particles/cell. No such reduction was evident when RAW cells were infected with he Ad.CMVLacZ virus. These results were confirmed by analysis of NFB DNA binding activity using EMSA. In these studies RAW cells were infected with either Ad.N17Rac1 or Ad.CMVLacZ for 48 h prior to LPS treatment and the preparation of nuclear extracts. As seen in Fig. 3A , Ad.N17Rac1, but not Ad.CMVLacZ, reduced NFB heterodimer complex formation (p50/p65) induced by LPS. The reduction in NFB DNA binding invoked by the expression of N17Rac1 was ϳ50% and closely paralleled findings from the luciferase reporter assays (Fig. 2B) . These results indicate that a significant fraction of LPS-induced TNF␣ secretion is mediated via Rac1 activation of NFB.
Constitutive Activation of Rac1 Mimics LPS Induction of NFB Activity and TNF␣ Secretion-As an alternative approach for demonstrating a causal link between NFB induction by Rac1 and TNF␣ secretion, we tested whether expression of a dominant, constitutively active, form of Rac1 (V12Rac1) could mimic the effects of LPS treatment and lead to the induction of both NFB and TNF␣ secretion. As seen in Fig. 2C (Fig. 2D) . EMSA analysis of cells expressing V12Rac1 demonstrated a direct correlation in the level of induced NFB DNA binding and TNF␣ expression (Fig. 3B) . Furthermore, both TNF␣ secretion and NFB DNA binding induced by expression of the constitutively active V12Rac1 mutant was nearly completely blocked by co-expression of an IkB␣ mutant that blocks NFB activation (IB␣ S32A/S36A), but not by LacZ (Fig. 3, B and C) . Taken together, these studies substantiate the hypothesis that Rac1 primarily induces TNF␣ production through the NFB pathway. Since these studies with V12Rac1 were performed in the absence of LPS stimulation, the results indicate that Rac1 activation is a major effector of the proinflammatory signaling cascade distal to LPS receptor activation.
LPS Activation of Rac1 and Constitutively Active V12Rac1 Mediate NFB-dependent TNF␣ Secretion through Activation of Both IKK␣ and IKK␤-Two adenoviral constructs expressing either the dominant mutant of IKK␣ (Ad.IKK␣KM) or IKK␤ (Ad.IKK␤KA) were generated to elucidate mechanisms by which Rac1 activates NFB-dependent TNF␣ secretion. As shown in Fig. 4A , both recombinant constructs produced HAtagged IKK subunits as detected by Western blot following infection in HeLa cells. We next sought to determine whether both IKK␣ and IKK␤ were required for Rac1 mediated activation of NFB and subsequent TNF␣ expression. Two experimental conditions were evaluated, LPS induction of Rac1 and constitutive activation of Rac1 (using infection with Ad.V12Rac1) in the absence of LPS. As shown in Fig. 4 , both LPS treatment and expression of V12Rac1 stimulated TNF␣ secretion (Fig. 4B) and NFB-dependent transcription (Fig.  4C) . LPS-induced TNF␣ secretion was most significantly inhibited following infection at the highest multiplicity of infections with Ad.IKK␤KA (6.1-fold) as compared Ad.LacZ infected controls. Ad.IKK␣KM infection at an identical multiplicity of infection led to a 1.7-fold blunting of LPS-induced TNF␣ secretion. Similarly, V12Rac1-induced TNF␣ secretion was more significantly blocked by IKK␤KA (5.1-fold) as compared with Ad.IKK␣KM (2.5-fold). Interestingly, IKK␤KA preferentially inhibited NFB-dependent transcription following LPS stimulation (30-fold) or expression of V12Rac1 (18.2-fold) as compared with IKK␣KM (2.5-2.9-fold) (Fig. 4D) . These finding suggest that IKK␤ may play a more dominant role than IKK␣ in NFB transcriptional activation following LPS induction of Rac1. However, the ϳ50% reduction in NFB transcriptional activity by IKK␣KM is somewhat different than previous reports suggesting little or no contribution of IKK␣ to IKK activity following proinflammatory stimuli (51, 52) . This difference may be attributable to the higher level of transgene expression achieved in the current study with recombinant adenoviral vectors.
LPS Stimulation of RAW Cells Leads to the Generation of Superoxide Radicals-The assembly of NADPH oxidase has been previously shown to be activated in neutrophils by exposure to bacterial LPS (31) . In neutrophils, this NADPH oxidase complex is responsible for the generation of superoxide, an important component of antibacterial activity in respiratory burst. Unlike neutrophil NADPH oxidase gp91, which as a transmembrane protein generates superoxides topologically in the extracellular compartment, other families of NADPH oxidases that generate intracellular superoxide proposed to act as second messengers important to intracellular signaling pathways have been recently identified (53) (54) (55) . In order to test whether LPS treatment leads to the generation of ROS, ESR was performed using the spin trap, DMPO (46) . As seen in Fig.  5C , treatment of RAW cells with LPS gave rise to significant levels of DMPO/ ⅐ OH spin adduct. Generation of LPS-induced DMPO/ ⅐ OH was significantly attenuated by infection with the dominant negative Ad.N17Rac1 (Fig. 5D) . In contrast, expression of the constitutively active V12Rac1 mutant gave rise to extremely high levels of DMPO/ ⅐ OH even in the absence of LPS stimulation (Fig. 5E ). This was not seen when the N17Rac1 negative mutant form of the protein was expressed in the absence of LPS (Fig. 5B) .
Although these data are consistent with the generation of hydroxyl radicals following LPS stimulation, they presently cannot discriminate between superoxides as the precursor ROS responsible for DMPO adducts seen in our studies. DMPO radicals are, at least in part, a precursor ROS formed following LPS stimulation (Fig. 7) . Furthermore, pretreatment of RAW cells with purified superoxide dismutase enzyme quenched the majority of LPS-induced O 2 . production (Fig. 7) . Both the DHE of RAW cells induces the production of ROS as determined by ESR. Although Ad.N17Rac1 expression reduced the production of ROS radicals in response to LPS treatment, the absolute requirement for ROS in the activation of NFB and subsequent TNF␣ production remains unclear. Two potential hypotheses could explain the current findings. First, ROS generated by activated Rac1 could be an unrelated effect of activating this pathway and may not be required for NFB activation or TNF␣ expression. Alternatively, Rac1-activated ROS production could be integral to the activation of NFB and TNF␣ expression. In order to differentiate between these two potential mechanisms, we performed studies evaluating LPS-induced NFB transcriptional activation and TNF␣ production under conditions where intracellular ROS were quenched by the use of chemical scavengers. These studies utilized two chemical scavengers, PDTC and NAC, which have been shown to quench superoxides (60), hydrogen peroxide (61, 62), and hydroxyl radicals (60, 62) . RAW cells were treated with increasing concentrations of either PDTC or NAC for 1 h at 37°C prior to LPS treatment. As seen in Fig. 8A, 34 and 61% reductions of TNF␣ expression were obtained when RAW cells were treated with 25 or 100 M PDTC, respectively. Similarly, treatment of RAW cells with 25 mM NAC reduced TNF␣ production by 54%. In order to assess the effect of these antioxidants on NFB transcriptional activity, studies were performed using RAW cells preinfected with the luciferase reporter virus Ad.NFBLuc (m.o.i. of 5000 DNA particles/cell) prior to treatment with antioxidants (PDTC or NAC) and LPS treatment (Fig. 8B) . These results demonstrated that LPS-induced NFB-mediated luciferase activity was reduced in a dose-dependent fashion when RAW cells were treated with these antioxidants. Interestingly, the antioxidant invoked reduction in NFB transcriptional activation was much more complete than their effect on TNF␣ secretion. Together with earlier findings, these results support the hypothesis that Rac1-mediated ROS production may primarily act to induce NFB activation following LPS stimulation. However, it is also clear that activation of the Rac1 signaling cascade and subsequent ROS production accounts for only a portion of the LPS-mediated cellular responses leading to expression of TNF␣.
CD14 Blocking Antibodies Decrease LPS-induced TNF␣ Secretion Independent of Rac1-Our results thus far demonstrate that Rac1 plays a critical role in ROS-mediated activation of NFB and subsequent TNF␣ secretion. However, since N17Rac1 blocked only about half of the LPS-induced TNF␣ production, our results also suggest that alternative pathways likely contribute to the activation of TNF␣. This is consistent with previous reports of both CD14-dependent (16, 21, 22) and CD14-independent (24 -27) pathways in the mediation of LPSinduced TNF␣ expression. Therefore, it seemed essential to investigate a possible association of Rac1 with CD14. In an initial effort to address this question, CD14-dependent pathways were blocked using CD14 blocking antibodies and the effects on Rac1 activation and TNF␣ production were evaluated. The blocking antibody used, RmC5-3, has previously been demonstrated to block LPS-induced CD14-mediated signaling pathways (63, 64) . As seen in Fig. 9A , treatment of RAW cells with RmC5-3 CD14 blocking antibodies prior to LPS stimulation significantly reduced TNF␣ secretion in a dose-dependent fashion. In contrast, no such reductions were observed in cells treated with control anti-mIgG antibody. These findings demonstrated a partial reduction in TNF␣ expression following inhibition of the CD14 receptor pathway that was similar in magnitude to the effects observed when Rac1 was inhibited by N17Rac1 expression. To begin to address whether Rac1 acts through CD14-dependent or -independent pathways, the level of GTP bound, activated Rac1 was assessed following treatment of RAW cells with anti-CD14 antibodies in the presence or absence of N17Rac1 expression. If Rac1 activation occurred through a pathway independent of CD14, we would expect to see no effect of anti-CD14 on the level of GTP bound Rac1. Results from this analysis (Fig. 9B) are consistent with the hypothesis that Rac1 is independent of CD14, since the blocking antibodies had no detectable influence on Rac1 activation. In contrast, N17Rac1 expression clearly decreased the level of GTP bound Rac1. We hypothesized that if these two pathways are acting in parallel, treatment with CD14 blocking antibodies and Ad.N17Rac1 should be capable of inhibiting the majority of TNF␣ production following LPS stimulation. As anticipated, combined inhibition of Rac1 and CD14-dependent pathways demonstrated an additive effect on reducing TNF␣ secretion (74 Ϯ 6%), which was greater than inhibiting Rac1 (44 Ϯ 6%) or CD14 (35 Ϯ 7%) individually (Fig. 9C) . These effects demonstrated a clear dose response to inhibitor (i.e. multiplicity of infection of Ad.N17Rac1 or concentration of anti-CD14 antibody) and were not seen with the control vector Ad.CMVLacZ or with the control isotype matched antibody. In summary, our overall findings suggest that LPS-induced Rac1 activation stimulates NFB activation and subsequent TNF␣ expression through ROS production in a CD14-independent manner.
LPS Differentially Regulates the Expression of TLR in RAW Cells-Results thus far have suggested that Rac1 mediates LPS activation of NFB through the production of ROS by a mechanism that is independent of CD14. However, the identity of the Rac1-linked receptor remains unknown. LPS is known to exert its effects on cells through the activation of Toll-like receptors. To date, numerous murine TLR genes have been identified (65) . TLR4 is widely accepted as a primary mammalian LPS sensor (66, 67) .
Although the function of TLR2 is somewhat controversial (68, 69) , TLR2 has also been shown to mediate LPS-induced cellular signaling (70, 71) . Interestingly, it has been recently reported that Staphylococcus aureus induction of TLR2 leads to Rac1-dependent NFB activation in THP-1 cells (72) . Importantly, oligomerization of TLR receptors has been suggested to create LPS-specific signaling receptors functionally distinct from the conventional CD14-TLR4 pathway (73) . For example, TLR6 and TLR2 have been shown to cooperate in the activation of NFB leading to TNF␣ expression in RAW cells (74) . For these reasons, we examined the expression levels of TLR2, TLR4, and TLR6 following LPS stimulation of RAW cells using real time PCR. We reasoned that such information would prove valuable for the identification of candidate receptors responsible for ROS formation following LPS stimulation. To this end, RAW cells were treated with LPS at concentrations of 0.2 or 5 g/ml for 4 h and potential alterations in TLR mRNA levels were analyzed (Fig. 10) . Our results indicated that the relative level of TLR4 mRNA was reduced by 60% following LPS exposure as compared with a 70% increase in TLR2 mRNA. Interestingly, a 3-fold induction in TLR6 mRNA levels was detected after 4 h of LPS treatment. Our findings demonstrating an increase in TLR2 mRNA levels and a decrease in TLR4 mRNA levels following LPS challenge substantiate previously published recent reports (75) (76) (77) . The unique aspect of our finding, which has not been previously reported, is the up-regulation of TLR6 mRNA following LPS exposure. These results suggest that TLR2, TLR4, and TLR6 are all potential candidates that could mediate Rac1 activation in RAW cells. Furthermore, mRNA levels of these genes are differentially modulated following LPS challenge. The significance of these changes in response to LPS and the potential involvement of these Tolllike receptors in Rac1 signaling remain to be determined.
DISCUSSION
The number of deaths due to sepsis continues to rise worldwide (3). Despite extensive research, efficacious therapies for sepsis have yet to be developed (78) . Moreover, clinical trials using either pharmacological agents or monoclonal anti-endotoxin antibodies have not been successful (79 -82) . The failure to develop effective therapies for septic shock is partly due to our limited understanding of the signaling pathways involved in the generation of the septic proinflammatory state.
In the present report, we have provided the first description of a pathway linking the small GTP-binding protein Rac1 to LPS-stimulated ROS generation, NFB transcriptional activation, and subsequent TNF␣ expression (Fig. 11) . Several key features of LPS-induced Rac1 signal transduction should be noted. First, inhibition of Rac1 with the dominant negative mutant N17Rac1 blocked about half of both NFB transcriptional activation and the LPS-induced TNF␣ response. The same negative mutant blocked the majority of ROS formation induced by LPS. Second, the expression of the constitutively active form of Rac1 was capable of mimicking LPS-induced ROS formation, NFB activation, and TNF␣ induction in the absence of endotoxin stimulation. Third, chemical antioxidants blocked the majority of the LPS-induced NFB transcriptional activation and only a fraction (ϳ50%) of TNF␣ expression. Fourth, we have clearly shown that LPS treatment leads to the generation of superoxide radicals. Together, these findings suggest that LPS-induced Rac1 activation acts primarily to induce TNF␣ through a ROS-dependent NFB pathway.
Although the link between LPS activation of Rac1 and subsequent induction of NFB is strong, other pathways independent of Rac1 are also likely to influence the total level of NFB activation and TNF␣ production following LPS treatment. This is indicated by the finding that N17Rac1 expression blocked only half of the LPS-induced NFB DNA binding and transcriptional activity. If the inhibition of Rac1 by the dominant negative mutant were indeed complete (as was suggested by activity assays for GTP bound Rac1), this would suggest that other LPS-induced pathways must also activate NFB. In contrast, V12Rac1 induction of NFB and TNF␣ expression was nearly completely blocked by expression of the IB␣ dominant mutant, suggesting that although multiple LPS-stimulated pathways may activate NFB, the Rac1 component appears to in- FIG. 10 . LPS differentially regulates the expression of TLR genes. Relative mRNA expression levels of various TLR genes (TLR2, TLR4, and TLR6) were determined in LPS-treated or untreated controls using real time-PCR as described under "Experimental Procedures." RAW cells were treated with 0.2 and 5 g/ml LPS for 4 h at 37°C prior to analysis. For each sample, TLR mRNA levels were normalized to HPRT as an internal control. For each TLR gene, untreated controls were chosen as the reference point to which all LPStreated experimental samples were compared (untreated controls are normalized to 1). Data represent the mean (ϮS.E.) of four independent experiments. A statistically significant difference between untreated and LPS-treated samples, as determined by the paired Student's t test (p Ͻ 0.05), is denoted by †.
FIG. 11. Schematic model for the role of Rac1 in LPS-mediated NFB activation.
Our results suggest the existence of an alternative ROS-dependent Rac1 activation pathway, which appears to be independent of the CD14 receptor but still capable of activating NFBmediated TNF␣ expression. As shown, a dominant inactive form of Rac1 (N17Rac1) or ROS scavengers (PDTC and NAC) inhibit the production of ROS, NFB activation, and TNF␣ production. In contrast, a constitutively active form of Rac1 (V12Rac1) augments these events. Both IKK␣ and IKK␤ appear to be involved in Rac1-mediated NFB activation. This is supported by the finding that the dominant mutants IKK␣(K44M), IKK␤(K44A), and IkB␣(S32A/S36A) all inhibit NFB activation following expression of V12Rac1. The LPS receptor that interacts with Rac1 in this pathway is currently unknown.
duce TNF␣ primarily through NFB activation. Parallel pathways involved in NFB activation, which converge at the level of the IKK complex, have previously been identified (83) . These studies have demonstrated that NIK and MEKK1 can independently activate the IKK complex through distinct regulation of IKK␣ and IKK␤. In the case of LPS stimulation, our studies demonstrate that both IKK␣ and IKK␤ play a role in the activation of TNF␣ expression. Similar effects of these IKK mutants on TNF␣ expression were noted in V12Rac1 expressing cells, supporting the notion that the IKK complex is a predominant target of LPS-mediated Rac1 activation. Interestingly, the inhibition of IKK␤ more significantly attenuated (18 -30-fold) NFB activation than did inhibition of IKK␣, as noted in luciferase assays of LPS-treated and V12Rac1-expressing cells. Such findings suggest that IKK␤ plays a more dominant role than IKK␣ as an effector of Rac1 activation of NFB.
Our studies using CD14 blocking antibodies suggest that LPS-mediated Rac1 activation of NFB and TNF␣ may be independent of the CD14 receptor. Testing LPS-induced Rac1 activation in CD14-deficient murine macrophages may confirm these observations. In this regard, CD14-dependent pathways of sepsis have recently been identified and they are increasing in number (66, 84 -86) . Human macrophage receptors other than CD14, such as CD11/CD18 integrins, have also been reported to bind to the lipid A region of Gram-negative bacteria (87, 88) . Similar levels of TNF␣ release were observed from CD14-deficient and wild type macrophages stimulated by whole E. coli (89) . In this particular case, it was demonstrated that CD11b/CD18 receptors compensated for LPS responsiveness in the absence of CD14 receptor. The fact that intracellular Toll-like receptor activation can initiate signaling pathways, in the absence of CD14 and long after particle internalization in phagolysosomes, should also be considered (90) . It is also interesting to note that lipopolysaccharide structure can influence the pathways activated in LPS-induced macrophage response (i.e. CD14-dependent versus CD14-independent (25) ).
It is believed that CD11b/CD18 integrin-mediated LPS responsiveness is conducted through the same downstream signaling elements as CD14 (91) (92) (93) (94) . Therefore, although Rac1 responsiveness appears to be CD14 independent in our preliminary studies, this would not rule out the possibility that similar downstream molecules (MYD88, IRAK, and TRAF6 etc.) are involved in LPS-induced Rac1 signaling. It should be noted, however, in our studies the effects of inhibiting both CD14 and Rac1 were additive, indicating the possibility of differences in the pathways. Consequently, from a therapeutic standpoint, our studies suggest that dual inhibition of both CD14 and Rac1-dependent pathways may provide the most efficacious strategies for inhibiting proinflammatory cytokine production induced by LPS in the course of sepsis.
